Objective-Hepatic ATP-binding cassette transporter A1 (ABCA1) plays the major role in maintaining plasma high-density lipoprotein levels by producing cholesterol-accepting nascent high-density lipoprotein, whereas peripheral ABCA1 is responsible for releasing cellular cholesterol. We previously reported that in rodents, cholesterol depletion reduces ABCA1 expression in peripheral but not hepatic cells by increasing a liver-specific ABCA1 transcript via the sterol regulatory element-binding protein-2 system. However, the regulatory element is not conserved in humans. Here we investigated the mechanism of sterol-regulated human hepatic ABCA1 gene expression. Methods and Results-ABCA1 mRNA variant type L3 is a novel and human-liver-specific transcript accounting for Ϸ25% of total ABCA1 mRNA in the liver and is induced by cellular cholesterol depletion. Specific knockdown or forced expression revealed that type L3 produces functional ABCA1 protein in cholesterol efflux. We identified a regulatory enhancer element for L3 expression lying within intron 3 of the human ABCA1 gene, to which hepatocyte nuclear factor (HNF) 4␣ binds in response to cholesterol depletion. HNF4␣ knockdown abolished induction of liver-specific L3 and L2b transcripts (and consequently the liver-type response of ABCA1 expression to cellular cholesterol status) and diminished cholesterol efflux activity.
T he ATP-binding cassette transporter A1 (ABCA1) is a plasma membrane transporter involved in cholesterol and phospholipid transport that plays a critical role in apolipoprotein A-I (apoA-I)-dependent biogenesis of high-density lipoprotein (HDL). 1,2 ABCA1 gene mutations cause Tangier disease and familial HDL deficiencies characterized by a near absence of circulating HDL. The essential role of ABCA1 in HDL biogenesis was further demonstrated by studies that included ABCA1 overexpression and deletion in mice. 3, 4 Although ABCA1 is widely expressed in many tissues, gene-targeting studies in mice revealed that hepatic ABCA1 is responsible for approximately 80% of plasma HDL production. 5 Further studies suggested that the role of hepatic ABCA1 in maintaining plasma HDL levels is distinct from that of extrahepatic ABCA1. 6 Hepatic ABCA1 is critical for phospholipidating lipid-free apoA-I to generate cholesterolpoor early nascent HDL particles that in turn provide efficient cholesterol acceptors for peripheral cells, whereas ABCA1 in peripheral cells, such as macrophages and fibroblasts, mediates release of excess cellular cholesterol by generating mature HDL particles, 6 probably in a sequential collaboration with ABCG1. 7 The proposed roles of hepatic and peripheral ABCA1 are consistent with a classic model of the reverse cholesterol transport pathway, in which HDL transports excess cholesterol from peripheral cells to the liver, where cholesterol can be converted into bile acids for excretion. 8 Hepatic and peripheral ABCA1 are under distinct gene regulation. ABCA1 expression in peripheral cells is upregulated by a liver X receptor (LXR)-driven promoter system in response to cholesterol loading. 9 Conversely, cholesterol depletion or treatment of cells with statins that inhibit endogenous LXR ligand synthesis represses ABCA1 expression, 10, 11 collectively indicating that cellular cholesterol homeostasis is stringently controlled by the LXR-ABCA1 pathway in peripheral cells. In contrast, hepatic ABCA1 expression appears to be unaffected by sterols as suggested by the failure of cholesterol feeding of mice to elevate hepatic ABCA1 expression 12, 13 and the inability of cholesterol depletion to repress expression. [14] [15] [16] [17] In the preceding study using rodents, 14 we identified a liver-specific ABCA1 mRNA variant and a corresponding promoter element driven by sterol regulatory element-binding protein-2 (SREBP-2), a transcription factor activated by cellular cholesterol depletion, in addition to the peripheral-type ABCA1 mRNA in the liver. Thus, cholesterol negatively and positively affects the liver-type SREBP-2 and peripheral-type LXR promoters, respectively, to control hepatic ABCA1 expression. This SREBP-2-and LXR-driven dual promoter system appears to ensure that hepatic ABCA1 expression is constant even under fluctuating cholesterol conditions and may be associated with ABCA1's specific role in producing cholesterol acceptors in the reverse cholesterol transport pathway. Recently, microRNA-33 was shown to contribute to sterol-responsive ABCA1 gene regulation. MicroRNA-33, located within the gene encoding SREBPs, inhibits the expression of ABCA1 and makes a significant contribution to hepatic ABCA1 and plasma HDL levels in mice. 18, 19 Thus, multiple systems are likely to regulate hepatic ABCA1 expression.
In human hepatoma HepG2 cells, ABCA1 mRNA levels are slightly augmented on statin treatment, 16, 17 which suggests that a liver-type regulation also occurs in humans. However, the SREBP-2 binding element (sterol regulatory element) in the liver-type promoter is not conserved in humans, suggesting that a different system may drive liver-specific ABCA1 expression in humans. We report here that hepatocyte nuclear factor (HNF) 4␣ regulates expression of liver-specific ABCA1 transcripts in response to cholesterol depletion.
Methods
An expanded Material and Methods section is available in the online-only Data Supplement. 5=-rapid amplification of cDNA end polymerase chain reaction (PCR), plasmid construction, cell culture, RNA extraction and quantitative real-time reverse transcription (RT)-PCR, Northern and Western blot analyses, RNA interference, reporter gene assays, cholesterol efflux assays, chromatin immunoprecipitation assay, electrophoretic mobility shift assay, avidin biotin-conjugated DNA assay, lentivirus infection, and statistical analysis are described in detail in the online-only Data Supplement.
Results

Expression of Liver-Specific ABCA1 mRNA Variants in Human Liver Tissue and Hepatic Cells
To identify liver-specific ABCA1 transcripts, we performed 5=-rapid amplification of cDNA end on total RNA extracted from human liver and identified 4 major bands ( Figure 1A Figure IA in the online-only Data Supplement), in addition to the previously described peripheral-type (type P) ABCA1 transcript. 14 In contrast, peripheral THP-1 cells had only type P transcript. Type L3 is a novel transcript that lacks exon 1/exon 2 and has a newly identified 303-bp sequence (exon L3) upstream of exon 3. Exon L3 appears to be unique to humans because of no homologous sequence in rodent ABCA1 genes. Type L2a and L2b were homologous to rodent types L and L=, which we previously identified 14 (Figure IA-IC in the online-only Data  Supplement) . Type L4a and L4b were similar to the human liver-type transcripts previously identified 20 and were expressed mainly in the liver ( Figure II in the online-only Data Supplement). Type L2b was less abundant compared with type L2a. Several minor transcripts, including those identified by Singaraja et al 20 and Cavelier et al, 21 are shown in Figure  ID in the online-only Data Supplement. All products identified here were spliced according to the GT-AG splicing rule.
Quantitative real-time RT-PCR (qRT-PCR) showed that newly identified type L3 and L2b variants were expressed exclusively in the liver, whereas type P was expressed in various human tissues ( Figure 2A ). Type L2a levels were not measured because there were no variant-specific regions in this transcript. To determine the abundance of type L3, L2b, or type P relative to that of total ABCA1 mRNA, we used variant-specific and universal RT-PCR probe/primers ( Figure  IA in the online-only Data Supplement) and a standard curve based on serial dilution of cDNAs containing 2 target sequences for the qRT-PCR probe (L3/universal, L2b/universal, or P/universal, respectively). The type L3 mRNA represented 26.2Ϯ9.4% of total ABCA1 mRNA in human liver RNA preparations (nϭ4), whereas type P and type L2b mRNA were estimated to be 33.4Ϯ5.5% and 12.3Ϯ4.8%, respectively, of total ABCA1 mRNA, indicating that type L3 is a novel and major ABCA1 transcript expressed in human liver. Type L3 was expressed in purified human hepatocytes at a higher level than that in the original total liver-cell preparations ( Figure 2B Type L3 and L2b mRNAs were highly expressed in human hepatoma cells (HepG2, Hep3B, and JHH-5 22 ) at levels comparable to that in human liver tissues (nϭ4) but undetectable in peripheral THP-1 cells ( Figure 2C ). The expression of type L3 and L2b transcripts was augmented by cholesterol depletion in 3 hepatoma cell lines, as was rodent type L. 14 Conversely, in all cell lines tested, type P mRNA expression decreased in response to cholesterol depletion, as was reported previously. 9 Type L4a and L4b mRNA levels were extremely low and undetectable in all cell lines (data not shown). The total ABCA1 mRNA level in hepatic cell lines was either unaffected or mildly elevated by cholesterol depletion, whereas for peripheral THP-1 cells, total ABCA1 mRNA declined similarly to type P mRNA levels. These findings indicate that ABCA1 mRNA expression in human hepatoma cell lines is composed of sterol-repressed (type L2 and L3) and sterol-augmented (type P) mRNA expression.
Type L3 Is a Major ABCA1 Transcript Producing a Functional ABCA1 Protein
We investigated whether type L3 mRNA encodes a functional ABCA1 protein using a short interfering RNA (siRNA) specific to the type L3 transcript. In cholesterol-depleted JHH-5 and Hep3B cells, transfection of type L3-specific siRNA effectively diminished type L3 mRNA expression without decreasing type L2b and type P mRNA levels ( Figure  3A) . Notably, specific knockdown of type L3 mRNA caused a significant reduction in the total ABCA1 mRNA ( Figure 3A ) and protein levels ( Figure 3B ). To exclude off-target effects, we repeated the experiments using 3 other siRNAs specific to type L3, and we confirmed that these siRNAs also effectively diminished type L3 mRNA and decreased total ABCA1 mRNA and protein expression ( Figure 3D and Figure IV) . Northern blot analysis confirmed the L3 mRNA knockdown and an accompanying decrease in total ABCA1 mRNA band ( Figure 3C ). Furthermore, siRNA treatment caused an Ϸ45% decrease in apoA-I-dependent [ 3 H]cholesterol efflux from JHH-5 cells under cholesterol-depleted conditions ( Figure  3E ). Also, 3 siRNAs to type L3 significantly decreased the mass of free cholesterol efflux under normal culture conditions ( Figure 3F ). Although type L3 ABCA1 mRNA lacks exon 2, which includes a known translation start codon, ATG 9,23 ( Figure 1B and Figure III in the online-only Data Supplement), the L3 transcript could be initiated at using the predicted start codon located at the 3=-end of exon L3 (Figures IC and III in the online-only Data Supplement). We constructed an expression vector of type L3 ABCA1 fusing green fluorescent protein to the C terminus and obtained JHH-5 cells stably expressing L3-ABCA1-green fluorescent protein, in which marked increases of ABCA1 expression and cholesterol efflux activity were observed ( Figure 3G and 3H). Together, these results clearly show that type L3 is a major transcript producing a functional ABCA1 protein in the liver.
Identification of the Type L3 Promoter and Its Cholesterol-Responsive Enhancer Elements
To explore the mechanisms by which type L3 transcripts were increased by cholesterol depletion, we searched for a possible promoter region for the L3 transcript in the region upstream of the putative transcription initiation site (ϩ1) for type L3 mRNA (1010 or 4208 bp) ( Figure 4A and 4B, Luc1-Luc3; Figure VI in the online-only Data Supplement). Although these regions did not have basal promoter activity and were unresponsive to cholesterol depletion in a luciferase assay, a reporter con- struct containing an element from ϩ426 to ϩ480 did show basal transcriptional activity and caused mild activation on cholesterol depletion ( Figure 4B, Luc5) , albeit at a level that is likely insufficient to produce a full response to sterols. The promoter activities of several genes are often regulated by distal enhancers. Sequence alignment of 5 mammalian ABCA1 genes identified a highly conserved region in intron 3 (positioned between ϩ3103 and ϩ3378 in humans) ( Figure  4A ; Figures VI and VII in the online-only Data Supplement). Therefore, we examined whether this region functions as an enhancer for the ABCA1 type L3 promoter by inserting the conserved region of intron 3 into the 3=-end of the poly A site ( Figure 4A ). We found that insertion of this region effectively enhanced type L3 promoter activity, and this activity was further amplified by cholesterol depletion (Figure 4C, Luc7) . Furthermore, introducing this region into a reporter plasmid driven by the SV40 promoter instead of the type L3 promoter potentiated both basal promoter activity and a sterol response ( Figure 4D, Luc9) . These results suggest that the conserved region in ABCA1 intron 3 functions as a distal enhancer of the type L3 promoter that could be responsible for upregulation under sterol-depleted conditions.
To identify the sterol-responsive elements in this enhancer region, we performed a deletion analysis in this region. Deleting the 5=-end up to ϩ3171 enhanced the promoter activity and sterol-mediated response (Luc10), whereas further deletion greatly diminished these effects ( Figure 4E contains a palindromic sequence box (P-Box) ( Figure 4E , upper scheme). In a similar fashion, 3=-end deletions up to ϩ3260 enhanced the promoter activity and the response to sterol depletion (Luc16), whereas deletion up to ϩ3247 (Luc17) markedly decreased the response, and further deletion up to ϩ3230 (Luc18) completely abolished these effects.
Accordingly, a reporter containing the region from ϩ3172 to ϩ3259 showed a strong response to sterol depletion ( Figure 4E , Luc19). Within this responsive region, deletion of either the 3=-end up to ϩ3247 or the region between ϩ3229 and ϩ3241 significantly repressed the sterol-mediated response ( Figure 4E , Luc20, Luc21). These results suggest that the P-box and the 2 elements (ϩ3247 to ϩ3259, ϩ3229 to ϩ3241) are required for the sterol-mediated response in the distal enhancer region in ABCA1 intron 3. A homology search detected consensus binding sequences for various transcription factors, suggesting that these elements (ϩ3230/ϩ3243 and ϩ3224/ϩ3256) could be binding sites for liver-enriched transcription factors such as HNF1 and HNF4, respectively (http://tfbind.ims.u-tokyo.ac.jp/; Figure 4E , upper scheme).
HNF4␣ Regulates Type L3 Promoter Activity Through Binding to the Distal Enhancer Elements
The role of liver-specific transcription factors HNF1␣ and HNF4␣ in the sterol-responsive distal enhancer activity within ABCA1 intron 3 was investigated. Whereas HNF4␣ expression effectively augmented type L3 promoter-enhancer activity in a distal enhancer region-dependent manner, HNF1␣ produced only minimal enhancement ( Figure 5A ). Expression of a dominant negative form of HNF4␣ lacking the AF-2 domain repressed its promoter-enhancing activity, especially under cholesterol-depleted conditions ( Figure 5B ). HNF4␣ expression also augmented the activity of a SV40 promoter-driven reporter gene containing the ABCA1 enhancer region ( Figure 5C , Luc22) but did not activate a construct that lacked the putative HNF4-binding site (Luc23). Deletion of the P-box (Luc24) or putative HNF1 site (Luc25) did not affect this HNF4␣-mediated augmentation. In addition, the activity of a reporter gene containing 4 tandem repeats of the HNF4-response element was enhanced by HNF4␣ expression (Luc26). These results indicate that the HNF4-element, but not the P-box nor putative HNF1-binding site, is critical for HNF4␣-mediated activation of ABCA1 expression. Data represent meansϮSD (nϭ3). SV40 indicates SV40 promoter. E and F, JHH-5 cells were treated under sterolsϩ or sterolsϪ conditions for 16 hours. E, Cells were subjected to chromatin immunoprecipitation (IP) assay using the indicated antibodies or control IgG. The immunoprecipitated region containing HNF4␣-response elements within the intron 3 enhancer region was amplified with polymerase chain reaction (PCR) using specific primers as described in Materials and Methods. The amplified PCR products were subjected to electrophoresis in a 2% agarose gel. Input indicates that genomes extracted from 2% of total lysates were amplified with PCR. F, The cell lysates were subjected to avidin biotin-conjugated DNA assays using 2 biotin-conjugated nucleotides (#1 or #2) as indicated in the top panel and, together with an aliquot of the lysates (input), immunoblotted (IB) with anti-HNF4␣ antibody. The arrow and asterisk indicate HNF4␣ protein and nonspecific bands, respectively.
We performed a chromatin immunoprecipitation assay to investigate whether endogenous HNF4␣ protein associates with chromatin via this putative HNF4-binding site. Clear bands were detected when chromatin from cholesteroldepleted JHH-5 cells was immunoprecipitated with antibodies against HNF4␣, indicating that a tight association of endogenous HNF4␣ protein with the conserved intron 3 region was induced by cholesterol depletion (Figure 5E ). Additionally, an in vitro DNA binding assay confirmed the association of HNF4␣ with this site. Endogenous HNF4␣ in lysates of cholesterol-depleted cells reacted with biotinconjugated oligodeoxynucleotides corresponding to the ABCA1 region from ϩ3223 to ϩ3262 that includes the HNF4-response element (#1), but not oligonucleotides that lacked this element (#2) ( Figure 5F ). Furthermore, electrophoretic mobility shift assay also confirmed the association of HNF4␣ with this binding site ( Figure VIII in the online-only Data Supplement). These results indicate that the putative HNF4-binding site on ABCA1 intron 3 is authentic.
HNF4␣ Is Required for Expression of Liver-Specific ABCA1 mRNA and Protein in Response to Sterol Depletion
The role of HNF4␣ in liver-type ABCA1 mRNA variant expression was investigated using siRNA knockdown. In JHH-5 cells, 3 siRNAs against HNF4␣ effectively reduced HNF4␣ mRNA and protein expression ( Figure 6A and 6B ). HNF4␣ knockdown resulted in the reduced expression of type L3 and also type L2b but not type P transcripts under sterol-depleted conditions ( Figure 6A , black bars). Consistently, expression of total ABCA1 mRNA and protein was reduced by HNF4␣ knockdown under sterol-depleted conditions ( Figure 6A and 6B ). Reduction of type L3 and total ABCA1 mRNA was also confirmed by Northern blot ( Figure  V in the online-only Data Supplement). In the presence of cholesterol, however, HNF4␣ knockdown did not affect the expression of ABCA1 transcripts ( Figure 6A, white 
Discussion
The liver is the major source of apoA-I, and hepatic ABCA1 is responsible for producing the majority of plasma HDL. 5, 6 Hepatic ABCA1 has a specific role in producing early nascent HDL particles, 6 and its genetic regulation is distinct from extrahepatic ABCA1. 14 In this study, we investigated the regulation of ABCA1 expression in human liver cells and discovered a liver-specific regulatory system in humans. Among the liver-specific variants (types L2a/b, L3, L4a/b), type L3 is a novel ABCA1 transcript containing a humanspecific exon L3 and is a major transcript accounting for Ϸ25% of total ABCA1 mRNA in human liver. The ABCA1 protein translated from type L3 transcript lacks the amino-terminal 21 amino acids, because the first ATG codon resides in the 3=-end of exon L3 ( Figure III in the online-only Data Supplement). Although early studies showed that an ABCA1 expression construct lacking the 60 amino-terminal amino acids does not produce a functional protein in cells, 24 specific siRNAs against type L3 efficiently reduced ABCA1 protein and cholesterol efflux. Moreover, transfection of L3-ABCA1 expression vector into JHH-5 cells augmented ABCA1 protein and cholesterol efflux activity, demonstrating that the L3-derived ABCA1 variant protein is stable and functionally active.
HNF4␣ Regulates Hepatic ABCA1 Gene Expression in Humans
When cellular cholesterol is depleted, the liver-specific type L3 and L2b transcripts are induced and positively regulate ABCA1 protein expression ( Figure XIII in the online-only Data Supplement). We previously discovered that SREBP-2, a transcription factor activated on cellular cholesterol depletion, 25 upregulates the rodent liver-type (type L) ABCA1 promoter. 14 However, the SREBP-2 binding element (sterol regulatory element) in the rat promoter is not conserved in humans ( Figure  XIVA in the online-only Data Supplement), and the human type L2 promoter containing this region is not activated by cholesterol depletion ( Figure XIVB in the online-only Data Supplement). In humans, we found a critical role of the liver-enriched transcription factor HNF4␣ in hepatic ABCA1 expression. Knockdown of HNF4␣ abolished inductions of L3 and L2b mRNA and, conversely, forced expression of HNF4␣ in JHH-5 cells increased them. Altered L3 and L2b mRNA levels led to substantial changes in total ABCA1 mRNA and protein expression and in cholesterol efflux activity. Thus, HNF4␣ is required for the induction of liver-specific ABCA1 transcripts, including types L3 and L2b, and thereby modulates ABCA1 expression and HDL generation.
We identified a regulatory enhancer element for L3 expression lying within intron 3 of the human ABCA1 gene, to which HNF4␣ binds and at which HNF4␣ augments the L3 promoter-enhancer activity in response to cholesterol depletion. Because HNF4␣ expression was increased on cholesterol depletion and HNF4␣ knockdown abolished the L3 and L2b induction, it is likely that the HNF4␣ level or activity (via dephosphorylation 26 ) determine the sterol-responsive L3 and L2b expression. However, it is more likely that along with HNF4␣, several transcription factor(s) cooperatively regulate the L2 and L3 expression, because we identified several elements (and region) responding to cholesterol depletion in the intron 3-enhancer and the L3 promoter ( Figure  4E ). In addition, in human JHH-5 cells, SREBP-2 knockdown partly diminished the L3 and L2b induction on sterol depletion ( Figure XV in the online-only Data Supplement). Thus, SREBP2 partially regulates human hepatic ABCA1 expression through distinct mechanism from that in rodents. Although decreased HNF4␣ expression ( Figure XV in the online-only Data Supplement) may be responsible for this effect, it is possible that SREBP-2 directly (via some unknown sterol regulatory element) or indirectly (via interaction with HNF4␣) regulates L3 and L2b mRNA expression. Decreased type P mRNA expression by SREBP-2 knockdown is probably due to the decreased supply of endogenous ligands for LXR. 27 HNF4␣ knockdown resulted in the reduced expression of types L3 and L2b but not type P. Although we have confirmed that neither LXR regulating type P promoter nor microRNA-33 regulating ABCA1 mRNA stability was affected by HNF4␣ knockdown, further investigation on chromatin-loop or transcription factors is needed to understand the mechanism.
Because the HNF4 binding site located in ABCA1 intron 3 is conserved among mammals ( Figure III in the online-only Data Supplement), HNF4␣ may also regulate the liver-type
